Free Trial

Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis

+0.13 (+1.44%)
(As of 05/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
3.41 million shs
Average Volume
5.22 million shs
Market Capitalization
$2.18 billion
P/E Ratio
Dividend Yield
Price Target

Recursion Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
56.5% Upside
$14.33 Price Target
Short Interest
24.98% of Float Sold Short
Dividend Strength
News Sentiment
0.63mentions of Recursion Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$2.87 M Sold Last Quarter
Proj. Earnings Growth
From ($1.60) to ($1.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.73 out of 5 stars

Medical Sector

567th out of 917 stocks

Biological Products, Except Diagnostic Industry

81st out of 148 stocks

RXRX stock logo

About Recursion Pharmaceuticals Stock (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology and data science company based in Salt Lake City, Utah. Founded in 2013, the company's vision is to revolutionize drug discovery by integrating cutting-edge technologies across biology, chemistry, automation, data science, and engineering. Recursion's innovative approach focuses on using human cell models of diseases, capturing microscopic images to build extensive biological datasets, and employing advanced computational techniques, including artificial intelligence, to decode biology and identify disease-associated patterns.

Recursion Pharmaceuticals was incorporated in 2013 with the fundamental goal of industrializing drug discovery to accelerate the pace of identifying potential treatments for a wide range of diseases. The company aims to leverage technological innovations and data-driven insights to decode the complexities of cellular biology. Recursion aspires to transform the drug development landscape by combining AI with biological research and improving patient outcomes.

The company's key product offerings are centered around an array of novel drug candidates targeting various diseases. REC-994, currently in Phase 2 clinical trials, is being developed to treat cerebral cavernous malformation (CCM), a genetic disorder affecting the brain's blood vessels. REC-2282 is another promising candidate in Phase 2/3 clinical trials, intended to treat neurofibromatosis type 2. REC-4881, REC-3964, and a second compound with the same name, REC-4881, are also in various clinical trials for treating familial adenomatous polyposis, Clostridioides infection, and certain cancers. In addition to these clinical-stage products, Recursion Pharmaceuticals has preclinical-stage candidates, including RBM39 for HR-proficient ovarian cancer, REC-64151 targeting immune checkpoint resistance, and Anti-PD-(L)1, a small molecule to enhance sensitivity to immune checkpoint inhibitors in certain cancers.

Recursion's target market primarily comprises patients and healthcare providers seeking innovative and effective treatments for various diseases. The company's focus on rare diseases, neurological disorders, and cancer demonstrates its commitment to addressing critical unmet medical needs. Key customers for Recursion Pharmaceuticals include healthcare organizations, research institutions, and biotechnology companies collaborating in the pursuit of novel therapies.

The leadership team at Recursion Pharmaceuticals is driving the company's vision forward. Dr. Christopher C. Gibson, Ph.D., the Co-Founder, Chief Executive Officer, and Director, is a visionary leader with a deep understanding of the intersection between biology and AI. His strategic guidance has been instrumental in shaping Recursion's path to success. Ms. Tina Marriott Larson, the Chief Operation Officer and President, brings a wealth of operational expertise and a strong track record in scaling biotech ventures. Her leadership has facilitated efficient operations and resource allocation.

Over the past few years, Recursion Pharmaceuticals has shown significant revenue growth. Recently the company reported revenue representing an impressive year-over-year change of more than 100%. This surge in revenue signals strong market traction for the company's drug candidates and validates its innovative drug discovery approach. Key earnings metrics have also been favorable despite the negative value; the net profit margin and earnings per share have shown improvements. The company's financial performance reflects the significant investments made in research and development to advance its clinical and preclinical products. 

The company's debt levels are manageable, given the current financial position and potential for future growth. Recursion Pharmaceuticals has sufficient short-term assets to cover its current liabilities.

Recursion Pharmaceuticals' valuation metrics present an interesting profile compared to industry peers. While the stock has seen fluctuations, the average stock price forecast suggests that some analysts see the company as overvalued relative to its intrinsic worth. However, various factors may influence investor sentiment, including pipeline progress, clinical trial results, outside investment, and broader market dynamics. When looking at Recursion Pharmaceuticals' stock performance, we can observe fluctuations that correlate with significant events, such as clinical trial updates and regulatory developments. News related to partnerships and collaborations may also impact the stock's performance.

Recursion Pharmaceuticals operates in the biotechnology sector, specifically focusing on biological products and data science. The company has positioned itself as a leader in AI-driven drug discovery within this competitive landscape. Its innovative phenomics approach and strategic collaborations with renowned institutions and pharmaceutical giants set it apart from its peers. The company's focus on rare diseases and neurological disorders provides a strategic advantage, addressing unmet medical needs and potential market opportunities.

Recursion Pharmaceuticals has various growth opportunities due to its diverse clinical and preclinical pipeline. The expansion of clinical trials for existing candidates, successful regulatory approvals, and potential partnerships can drive future revenue growth. Additionally, the company's platform and AI-driven approach have the potential to identify new drug targets and expand therapeutic areas, presenting exciting growth prospects.

Like any biotechnology company, Recursion Pharmaceuticals faces inherent risks and challenges in drug discovery and development. Clinical trials carry uncertainties, and setbacks or failures can impact the stock price and investor sentiment. The competitive landscape poses challenges that require continued innovation and differentiation. Additionally, regulatory requirements and potential delays in approvals can influence the company's financial performance.

Recursion Pharmaceuticals employs robust risk management strategies to mitigate risks, including careful portfolio diversification across therapeutic areas, close monitoring of clinical trial progress, and prudent financial management. Collaboration with industry leaders and academic institutions strengthens the company's pipeline and risk-sharing capabilities.

RXRX Stock Price History

RXRX Stock News Headlines

The Next Drug You Take May be Designed By A.I. (RXRX)
Three stocks could give investors a better way to tap into A.I.'s future potential inside drug development, an industry that is set to grow at 29.6% until 2030
2 Stocks That Could 10x by 2035
See More Headlines
Receive RXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$44.58 million
Book Value
$1.69 per share


Free Float
Market Cap
$2.18 billion
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Christopher C. Gibson Ph.D. (Age 41)
    Co-Founder, CEO & Director
    Comp: $806.72k
  • Ms. Tina Marriott LarsonMs. Tina Marriott Larson (Age 49)
    COO & President
    Comp: $702.24k
  • Dr. Blake C. Borgeson Ph.D. (Age 42)
    Co-Founder & Director
    Comp: $40k
  • Dr. Michael Secora Ph.D. (Age 41)
    Chief Financial Officer
    Comp: $629.78k
  • Dr. David J. Mauro M.D. (Age 59)
    Ph.D., Chief Medical Officer
    Comp: $674.74k
  • Kevin Leggat
    Vice President of Finance & Accounting
  • Mr. Benjamin Mabey M.S. (Age 41)
    Chief Technology Officer
  • Mr. Jared Allenbach
    Senior Director of Investor Relations
  • Mr. Nathan Hatfield
    Chief Legal Officer & General Counsel
  • Mr. Ryan Kelly
    Chief Communications Officer

RXRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Recursion Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Recursion Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RXRX shares.
View RXRX analyst ratings
or view top-rated stocks.

What is Recursion Pharmaceuticals' stock price target for 2024?

4 Wall Street analysts have issued 12 month target prices for Recursion Pharmaceuticals' shares. Their RXRX share price targets range from $10.00 to $17.00. On average, they anticipate the company's stock price to reach $14.33 in the next twelve months. This suggests a possible upside of 56.5% from the stock's current price.
View analysts price targets for RXRX
or view top-rated stocks among Wall Street analysts.

How have RXRX shares performed in 2024?

Recursion Pharmaceuticals' stock was trading at $9.86 on January 1st, 2024. Since then, RXRX stock has decreased by 7.1% and is now trading at $9.16.
View the best growth stocks for 2024 here

When is Recursion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our RXRX earnings forecast

How were Recursion Pharmaceuticals' earnings last quarter?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) posted its quarterly earnings results on Thursday, May, 9th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.04. The company had revenue of $13.80 million for the quarter, compared to analysts' expectations of $11.10 million. Recursion Pharmaceuticals had a negative trailing twelve-month return on equity of 79.96% and a negative net margin of 765.90%. Recursion Pharmaceuticals's revenue was up 14.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.34) EPS.

When did Recursion Pharmaceuticals IPO?

Recursion Pharmaceuticals (RXRX) raised $306 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 18,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets acted as the underwriters for the IPO.

Who are Recursion Pharmaceuticals' major shareholders?

Recursion Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (10.26%), Vanguard Group Inc. (6.82%), Sumitomo Mitsui Trust Holdings Inc. (4.42%), Nikko Asset Management Americas Inc. (4.42%), Platinum Investment Management Ltd. (0.77%) and Bellevue Group AG (0.18%). Insiders that own company stock include Blake Borgeson, Christopher Gibson, Dean Y Li, Michael Secora, Mubadala Investment Co Pjsc, Shafique Virani, Terry-Ann Burrell, Tina Marriott, Tina Marriott Larson and Zavain Dar.
View institutional ownership trends

How do I buy shares of Recursion Pharmaceuticals?

Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RXRX) was last updated on 5/25/2024 by Staff

From Our Partners